GlassScriptPhysician profile
Julie A Shellhouse
NPI 1780675579
$1,170.67
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $169 · 2021: $73.18 · 2022: $25.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $190.82 | 2019-2020 | |
| Novo Nordisk INC | $176.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $120.31 | 2019 | |
| Amgen INC. | $97.64 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $72.63 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.34 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $39.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.21 | 2019 | |
| Ironshore Pharmaceuticals INC. | $30.73 | 2019 | |
| Mylan Specialty L.P. | $30.14 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.19 | 2019 | |
| Supernus Pharmaceuticals, INC. | $25.61 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $25.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.32 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.35 | 2019-2020 | |
| Ucb, INC. | $15.95 | 2020 | |
| Amarin Pharma, INC. | $12.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.81 | 2019 | |
| Lilly USA, LLC | $12.81 | 2019 | |
| Emd Serono, INC. | $11.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Shellhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.